CAMP4 Therapeutics Corporation CAMP 深 沪
等待开盘 07-02 09:30:00 美东时间
4.34
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 4.34
- 总市值 22.54万
- 52周最高 7.75
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.32
- 委 比 0.00%
- 总股本 5.19万
- 历史最高 12.30
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.40
- 每 手 1
- 风险率 1.39%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Positive Report for CAMP4 Therapeutics Corporation (CAMP) from J.P. Morgan
J.P. Morgan analyst Anupam Rama upgraded CAMP4 Therapeutics Corporation to a Bu...
06-23 20:37
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMP4 Therapeutics granted non-qualified stock options to three new employees on June 15, 2026, under Nasdaq Rule 5635(c)(4). The options, totaling 39,000 shares with an exercise price of $3.96, vest over four years. CAMP4 focuses on developing RNA-targeting therapeutics to treat genetic diseases by amplifying healthy protein levels.
06-19 20:05
美股大行评级 | 潜在涨幅117.92%！摩根大通上调Camp4 Therapeutics目标价至9美元，维持"超配"评级
今日重点评级关注：摩根大通：上调Camp4 Therapeutics评级至"超配"，目标价从5美元升至9美元；Canaccord Genuity：维持Rhythm制药"买入"评级，目标价从143美元升至151美元
06-17 11:32
This Exxon Mobil Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. B of A Securities analyst Jean Ann Salisbury upgraded Exxon Mobil Corp (NYSE:XOM) from Neutral to...
06-16 20:01
美股大行评级 | 高盛上调美光科技目标价从400美元升至900美元；斯马克、Cloudflare获多家公司上调目标价
今日重点评级关注：Ascendiant Capital：维持NextTrip"买入"评级，目标价从7美元升至7.5美元；Maxim Group：维持Zevra Therapeutics"买入"评级，目标价从25美元升至35美元
06-11 09:55
Chardan Capital Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $6.5
Chardan Capital analyst Keay Nakae initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Buy rating and announces Price Target of $6.5.
06-10 20:36
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMP4 Therapeutics Corporation granted a non-qualified stock option to purchase 5,000 shares of its common stock to a newly hired employee on May 15, 2026, as an inducement for employment. The option has a ten-year term, an exercise price of $4.31 per share, and vests over four years, with 25% vesting after one year and the remainder vesting in 36 monthly installments. The company focuses on developing RNA-targeting therapeutics to upregulate gen...
05-21 20:05
CAMP4 Highlights Preclinical Progress of SYNGAP1 Therapy
The latest announcement is out from CAMP4 Therapeutics Corporation ( ($CAMP) )....
05-14 21:38
Camp4 Therapeutics Q1 EPS $(0.32) Misses $(0.29) Estimate, Sales $1.294M Beat $300.000K Estimate
Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.29) by 10.34 percent. This is a 48.39 percent increase over losses of $(0.62) per share
05-08 04:49
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights
CAMP4 Therapeutics submitted its first clinical trial filing for CMP-002 in Australia, planning additional global filings in 2026 and initiating a Phase 1/2 trial in SYNGAP1 patients by late 2026. The company received Orphan Designation for CMP-002 from the EMA and entered a collaboration with CURE SYNGAP1 to support a natural history study. With $99 million in cash as of March 2026, CAMP4 expects its cash runway to extend into 2028.
05-07 20:05
